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Abstract
Background: Brain-derived neurotrophic factor (BDNF) has been implicated in cognitive performance and the
modulation of several metabolic parameters in some disease models, but its potential roles in successful aging
remain unclear. We herein sought to define the putative correlation between BDNF Val66Met and several metabolic
risk factors including BMI, blood pressure, fasting plasma glucose (FPG) and lipid levels in a long-lived population
inhabiting Hongshui River Basin in Guangxi.
Methods: BDNF Val66Met was typed by ARMS-PCR for 487 Zhuang long-lived individuals (age ≥ 90, long-lived
group, LG), 593 of their offspring (age 60–77, offspring group, OG) and 582 ethnic-matched healthy controls (aged
60–75, control group, CG) from Hongshui River Basin. The correlations of genotypes with metabolic risks were
then determined.
Results: As a result, no statistical difference was observed on the distribution of allelic and genotypic
frequencies of BDNF Val66Met among the three groups (all P > 0.05) except that AA genotype was
dramatically higher in females than in males of CG. The HDL-C level of A allele (GA/AA genotype) carriers
was profoundly lower than was non-A (GG genotype) carriers in the total population and the CG (P = 0.009
and 0.006, respectively), which maintained in females, hyperglycemic and normolipidemic subgroup of CG
after stratification by gender, BMI, glucose and lipid status. Furthermore, allele A carriers, with a higher systolic
blood pressure, exhibited 1.63 folds higher risk than non-A carriers to be overweight in CG (OR = 1.63, 95%
CI: 1.05 - 2.55, P = 0.012). Multiple regression analysis displayed that the TC level of LG reversely associated
with BDNF Val66Met genotype.
Conclusions: These data suggested that BDNF 66Met may play unfavorable roles in blood pressure and lipid
profiles in the general population in Hongshui River area which might in part underscore their poorer
survivorship versus the successful aging individuals and their offspring.
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Background
Brain-derived neurotrophic factor (BDNF) belongs to
the neurotrophin family and plays essential roles in mul-
tiple processes associated with neuronal proliferation,
differentiation and survival [1, 2]. It is mainly expressed
in central nervous system (CNS) including the cortex,
the hippocampus and limbic structures and is linked to
better cognitive status [3]. In addition, BDNF can cross
the blood-brain barrier in both directions, accounting
for more than 70% of serum BDNF in healthy humans
[4, 5]; serum BDNF concentration correlates closely with
the cortical BDNF level and reflects the BDNF level in
the brain [6].
Over the past decades, multiple lines of evidence have
implicated that BDNF is not only stimulating for nerve
growth and survival, but also exert nonneurotrophic
effects over blood pressure, glucose, lipid and energy
homeostasis in humans and model animals via central
pathways involved in appetite regulation and energy
expenditure [7–10]. It suppresses food intake, facilitates
glucose uptake in the brain, reduces hepatic glucose pro-
duction and converts white fat into brown fat in adipose
tissue, leading to energy dissipation, lowered blood glu-
cose and a lean phenotype; its downregulation in BDNF
knockout mice and diabetic patients is associated with
hyperphagic behavior, elevated blood glucose and choles-
terol, and obese phenotype [10]. Together, these findings
highlight the critical effects of BDNF on the mainten-
ance of energy homeostasis and CNS functionality, per-
turbed BDNF signaling may confer metabolic risks
which may further disrupt cognition and contribute to
neurodegenerative pathologies such as Alzheimer’s dis-
ease (AD), depression and Parkinson’s disease (PD). It is
thus reasonable to assume that long-lived individuals
with better cognition might harbor beneficial BDNF
genotypes and corresponding advantage profiles of
metabolic parameters.
The human BDNF gene is located on the short arm of
chromosome 11 at the boundary of 11p13 and 11p14
[11]. Several variants of BDNF gene have been reported
and the most frequent is the functional Val66Met
(c.196G > A, dbSNP: rs6265) polymorphism which sub-
stitutes a valine for a methionine at amino-acid residue
66 in the pro-BDNF protein, and the lower activity
(Met) allele of this polymorphism is associated with
reduced BDNF expression [12].
While BDNF Val66Met has been implicated as a
genetic risk factor in several psychiatric disorders (e.g.
schizophrenia, psychosis, major depression, anxiety, and
eating disorders), cognitive compromised disorders (e.g.
AD and PD) and metabolic syndrome [13–15], very little
data are available on its association with metabolic risks
in general population, especially in long-lived individuals
with good cognitive function.
The longevous population dwelling along the Basin of
Hongshui River in Guangxi Province of China is a repre-
sentative cohort of successful aging who have main-
tained better cognition [16] and escaped most of the
common aged-related disorders including hypertension,
diabetes, AD and PD and have been established as a co-
hort for longevity research for decades [17]. Herein, we
evaluated the putative association between BDNF Val66-
Met polymorphism and metabolic risk factors in this
population sample of long-lived men and women. This
work was presented at The 26th Great Wall In-
ternational Congress of Cardiology/Asia Pacific Heart
Congress 2015/International Congress of Cardiovascular
Prevention and Rehabilitation 2015 [18].
Methods
Study subjects
The participants investigated in the present work joined
the ongoing Bama Longevity Genetic Study (BLGS)
which was initiated in 2008 as described previously [18].
Herein, the long-lived group (LG) included 487 (men
200, women 287) nonagenerians/centenarians (mean
age ± SD, 93.28 ± 2.87 years) enrolled from native villages
along Hongshui River Basin through Bama, Fengshan,
Donglan and Du’an County of Guangxi Province, P. R.
China. The offspring group (OG) comprised 593 natural
children (son 333, daughter 260) of the studied nonagen-
erians/centenarians aged from 60 to 77 years (mean ±
SD, 67.55 ± 8.02). The control group (CG) consisted 582
(men 328, women 254) unrelated elderly aged from 60
to 75 years (mean ± SD, 65.27 ± 9.32) recruited from the
same residential area as the oldest olds without familial his-
tory of longevity. All subjects were of ethnically Zhuang,
apparently healthy with normal cognition and had no evi-
dence of any chronic disorder. They were on typical
Zhuang diet whose staple foods included maize, rice, bean
products, sweet potato and various local vegetables. The
meat they ate and the oil they used for cooking were mainly
pork and lard, respectively. All subjects could do as much
farm work or home work (e.g. baby caring) as they could.
Participants with a history of myocardial infarction, stroke,
hypertension, diabetes, AD and PD and a history of medi-
cation taking (at least 4 weeks prior to our enrollment)
were excluded. The current study was approved by the
Ethics Committee of Guangxi Medical University. All
participants could walk to the village clinics which were
usually half a mile away from their houses where they were
given verbal informed consents and their fingerprints (to
express consent) were obtained after they received a full ex-
planation of the study. Written informed consents were not
obtained because of their low educational level. The con-
sent procedure was also approved by the Ethics Committee
of Guangxi Medical University. An incentive of about ten
dollars was provided to each participant in the study [19].
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Epidemiological survey
Information on socio-demography and lifestyles was col-
lected with standardized questionnaires. Anthropometric
parameters including blood pressure, body height, body
weight, waist circumference and body mass index (BMI)
were measured or calculated in all groups as described
previously [20, 21]. Hypertension was defined as systolic
blood pressure (SBP) > 140 mmHg and/or diastolic blood
pressure (DBP) > 90 mmHg, and/or previous usage of
anti-hypertensive medications prior to the survey. Normal
weight, overweight, and obesity were defined as BMI < 24,
24 - 28, and > 28 kg/m2, respectively [20, 21].
Biochemical analyses
An overnight fasting venous blood sample of 8 mL was col-
lected for each subject, 4 mL of which was for serum separ-
ation and subsequent serological detections while the
remaining was for DNA extraction. Fasting plasma glucose
(FPG) was measured immediately by a blood glucose meter
(Accu-Chek Active, Roche, Germany). Total cholesterol
(TC), triglycerides (TG), low density lipoprotein cholesterol
(LDL-C) and high density lipoprotein cholesterol (HDL-C)
levels were assayed by enzymatic methods as previously
described [20]. Individuals with FPG > 7.1 mmol/L and
TC > 5.17 mmol/L and/or TG > 1.70 mmol/L were defined
as hyperglycemia and dyslipidemia, respectively [21].
Sample preparation and genotyping
Isolation of genomic DNA of leukocytes was performed
according to standard procedures. Genotyping of BDNF
Val66Met polymorphism was conducted by amplification
refractory mutation system-polymerase chain reaction
(ARMS-PCR) as described by Sheikh et al. [22]. The key
principle for this methodology is that oligonucleotides
with a mismatched 3’ residue do not function as a
primer in the PCR due to the lack of 3’ exonucleolytic
activity of Taq DNA polymerase. In brief, two sets of
PCR primers were used in the PCR where the first set
(P1, forward, 5′-CCTACAGTTCCACCAGGTGAGAA
GAGTG-3′ and P2, reverse, 5′-TCATGGACATGTT
TGCAGCATCTAGGTA-3′) was expected to the 401 bp
region containing the SNP of interest, while the second
set (P3 and P4, 5′-CTGGTCCTCATCCAACAGCTCT
TCTATaAC-3′ and 5′-ATCATTGGCTGACACTTTCG
AACcCA-3′, in which lower case letter indicated mis-
matched nucleotide) was allele specific and accounted
for the G→A substitution. PCR amplifications were
carried out in a 20 μL reaction volume containing 25 ng
of template DNA, primers (P1, P2, P3 and P4, 1.25 μmol/L
for each) and 10 μL of 2× Taq Master Mix (Beijing
ComWin Biotech Co.,Ltd, China) and were run in a
Biometra PCR system (TProfessional standard, Germany)
with a predenaturation at 94 °C for 5 min, followed by
30 cycles of 94 °C for 45 s, 62.5 °C for 60 s and 72 °C for
60 s and a final extension at 72 °C for 5 min. PCR products
(8 μL) were resolved on a 2% agarose gel for 30 min at
80 V and stained with Golden View I (Beijing Solorbio Co.,
Ltd, China). The 401 bp band represented the control
amplicon, whereas the 253 and 201 bp bands represented
the G and A allele-specific amplicons. For the genotyping
reliability, thirty randomly selected DNA samples (ten for
each genotype) were sequenced and the sequencing results
were all in agreement with that of PCR genotyping. Labora-
tory technicians who performed genotyping were masked
to clinical and serological data.
Statistical analyses
All data were analyzed using the SPSS 16.0 statistical
software package (SPSS Inc, Chicago, IL). Levels of
quantitative variables were presented as mean ± SD ex-
cept that TG levels were in medians (interquartile) due
to skewed distribution. Allelic and genotypic frequencies
were calculated directly. Hardy-Weinberg equilibrium
was computed for the expected genotype distribution
using the standard goodness-of-fit test. Difference in
genotypic and allelic distribution between groups was
estimated with chi-square test, and odds ratio (OR) and
95% confidential interval (CI) were used to indicate
relative risk. The statistical evaluation for the categorical
variables between groups was assessed by one-way
ANOVA test. The association of BDNF genotypes with
blood pressure, BMI, FPG and serum lipid variables was
evaluated using analysis of covariance (ANCOVA).
Multiple logistic analyses with stepwise modelling were
used to evaluate the association of blood pressure, BMI,
FPG and serum lipid levels with genotypes (GG = 1,
GA = 2, AA = 3) and several environment factors. In
all hypothetical tests, two-tailed values of P < 0.05
were considered statistically significant.
Results
Population characteristics and metabolic measures
Table 1 summarizes the demographic, clinical, and bio-
chemical characteristics of the three groups investigated.
OG and CG did not differ in terms of age (P > 0.05).
After adjustment for age and sex, DBP, TC, and LDL-C
were found to be higher while FPG was lower in LG as
compared with OG and/or CG. The blood levels of FPG,
HDL-C and LDL-C of OG were significant higher than
that of CG.
Genetic distribution
The distribution of the BDNF Val66Met alleles fit the
Hardy-Weinberg equilibrium. Its minor allele frequency
(MAF) in LG, OG and CG was 43.3%, 41.1% and 41.9 re-
spectively. Overall, the distribution of genotypic and allelic
frequency of this SNP did not differ across groups (P > 0.05)
except that females represented more AA genotype than
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males (P = 0.004, Fig. 1a) in control group under co-
dominant but not dominant model, which persisted through
sex stratification (P > 0.05 for all, Fig. 1a, b and c).
Genotypes and metabolic risk factors
Overall, no difference was observed between the impact
of BDNF rs6265 A genotype (GA/AA) and non-A geno-
type (GG) on waist circumference (WC), BMI, FPG, TG
and blood pressure in combined population and the
three groups under investigation (Fig. 2a, b, c, d, and e)
except that HDL-C level of A genotype carriers was dra-
matically lower than non-A carriers in the combined
population (P = 0.009) and in the controls (P = 0.006)
(Fig. 2f ). These trends did not change basically through
sex stratification (Fig. 3a-j). When BMI, FPG and lipid
status were taken into consideration, the SBP level of A
genotype carriers was noticeably higher (P = 0.023)
(Additional file 1: Figure S1, I) while HDL-C was lower
(P = 0.003) (Additional file 1: Figure S1, J) than non-A
carriers in the normal BMI subgroups of the controls;
lowered FPG level in the euglycaemic subfraction of LG
(P = 0.038) (Additional file 2: Figure S2, C), increased
SBP level in the hyperglycemic subfraction of OG
(P = 0.041) (Additional file 2: Figure S2, G) and low-
ered HDL-C level in the hyperglycemic subfraction
of CG (P = 0.001) (Additional file 2: Figure S2, J)
were found in individuals harboring A genotype versus
non-A genotype; a reduced FPG concentration in LG
normolipidemic subclass (P = 0.025) (Additional file 3:
Figure S3, C), a reduced BMI and HDL-C (P = 0.014 and
P = 0.004, respectively) (Additional file 3: Figure S3, B and
H) in OG normorlipidemic subclass and a raised BMI
level (P = 0.008) (Additional file 3: Figure S3, B) while a
compromised HDL-C level (P = 0.031) (Additional file 3:
Figure S3, J) in CG normorlipidemic subclass were
detected when A genotype bearers were compared with
non-A genotype bearers. Relative risk estimates showed
that allele A carriers have 1.63 folds higher risk to be
overweight in CG (OR = 1.63, 95% CI : 1.05 - 2.55) while
exhibit less risk to be hyperglycemic (OR = 1.039, 95%
CI = 0.619 - 1.742) and hyperlipidemic (OR = 1.198,95%
CI = 0.847 - 1.694) in LG, OG and CG as compared
with non-A carriers. Together, these data mainly dem-
onstrate that the mutant Met allele of BDNF gene may
have different impact on metabolic parameters in
different population and these impacts might be influ-
enced by different BMI, FPG and lipid status.
Correlation analyses
Multiple linear regression analyses revealed that BDNF
Val66Met genotype was reversely correlated with TC
level in LG. No correlation was observed between BDNF
Val66Met genotype and other metabolic parameters in
the three studied groups (Table 2).
Discussion
Instead of finding salutary genotypes of BDNF gene which
may account in part for better preservation of health in
the oldest olds and their offspring, we noted unexpectedly
an overrepresentation of BDNF 66 Met and its adverse
correlation with several metabolic parameters in the gen-
eral population living in the same area as the long-lived
families, which can also explain why local residents have
higher morbidity and mortality as compared to individuals
with exceptional longevity. These results are in concert
with some but not all observations from other research
groups. Here, the effect of this SNP on several common
metabolic risks is discussed basing on our data.
Table 1 Population characteristic and metabolic parameters of participants
Parameter LG (n = 487) OG (n = 593) CG (n = 582) F(χ2) P
Age (years) 93.28 ± 2.87*▲ 58.35 ± 9.06 58.18 ± 9.77 3239.680 0.000
Male/Female 200/287 333/260 328/254 31.813 0.000
WC (cm) 76.23 ± 9.14 75.08 ± 9.27 75.53 ± 9.41 0.340 0.712
BMI (kg/m2) 20.21 ± 3.63 21.68 ± 3.00 21.69 ± 3.24 0.022 0.978
FPG (mmol/L) 4.65 ± 1.18▲ 4.97 ± 1.80* 4.73 ± 1.52 8.070 0.000
SBP (mm Hg) 165.83 ± 26.15 137.81 ± 22.96 136.02 ± 23.56 0.618 0.539
DBP (mm Hg) 89.21 ± 13.17*▲ 85.15 ± 11.22 84.68 ± 11.31 4.020 0.018
PP (mm Hg) 76.61 ± 23.74 52.66 ± 19.81 51.34 ± 18.40 2.484 0.084
TC (mmol/L) 5.09 ± 1.00* 5.31 ± 1.13* 4.88 ± 1.00 28.690 0.000
TG (mmol/L) 0.97(0.45) 1.00(0.89) 0.95(0.66) 2.150 0.117
HDL-C (mmol/L) 1.61 ± 0.53 1.71 ± 0.57* 1.62 ± 0.50 3.353 0.035
LDL-C (mmol/L) 2.99 ± 0.87* 2.99 ± 1.04* 2.61 ± 0.92 27.325 0.000
Abbreviations: LG long-lived group, OG offspring group, CG control group, WC waist circumference, BMI body mass index, FPG fasting plasma glucose,
SBP systolic blood pressure, DBP diastolic blood pressure, PP pulse pressure, TC total cholesterol, TG triglyceride (presented as median and interquartile
range), HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
▲vs OG, P <0.05; *vs CG, P <0.05
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BDNF Val66Met and obesity
Obesity has been so common and has emerged as a
worldwide health problem due to its association with
increased risk of metabolic-related disorders. BMI is one
of the most important indicators for obesity assessment.
Several previous studies had implicated that the derived
Met allele of BDNF gene might down-regulate BDNF,
raise blood glucose concentration and predispose indi-
viduals to obesity [12, 13, 23, 24]. In the present work,
BDNF Met allele carriers with normal BMI and lipid
levels in OG displayed lower BMI whereas Met carriers
with normal lipids in CG exhibited higher BMI level and
risk of overweight, demonstrating a different impact
pattern of BDNF Met on body shape between the off-
spring of nonagenarians and the age-matched controls.
These findings are in accordance with those in several
previous studies but not in others. For instance, Estonian
adolescent girls bearing BDNF Val allele tended to have
lower BMI than who bear Met allele; Croatian Caucasian
children and adolescents who presented one or two Met
alleles were prone to obesity; Puerto Rican women living
in Boston with the GA or AA genotype were 50%
more likely to be overweight compared to GG carriers
[25–27]. Mounting experimental evidence supports
this association of Met variant with obesity: the derived
Met allele reduces the expression of BDNF, which plays
pivotal roles in the inhibition of excess calorie uptake (e.g.
vigorous appetite, bad dietary behavior and sedentary life-
style) and in the enhancement of energy expenditure (e.g.
acceleration of brown fat metabolism and the degener-
ation of serum level of TG, TC, and free fatty acids and
improvement of insulin resistance) [23, 28, 29]. On the
contrary, Met allele was either linked to thin phenotype in
British females, Chinese Han adolescents and Korean
smokers [30–32] or lacked of relationship with obesity in
German extremely obese children and adolescents and
underweight students [33]. The inconsistency of these
results indicates the uncertain association between BDNF
Fig. 1 Comparison of genotypic and allelic frequencies of the BDNF Val66Met among groups. a Genotypic frequency under co-dominant model,
females in CG represented more AA genotype than males (Chi-square test, χ2 = 11.263,P = 0.004). b Genotypic frequency under dominant model,
no difference among groups and between sexes. c Allelic frequency, no difference among groups and between sexes. *P < 0.05. Abbreviations:
LG, long-lived group; OG, offspring group; CG, control group; M, males; F, females
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Val66Met and obese phenotype which might be
modulated by other factors such as ethnic ba-
ckground, age, gender, living environment, dietary
structure and lifestyle [34]. Intriguingly, the Met
allele carriers in OG exhibited a lower BMI level,
implying that the descendants of nonagenarians may
endow other unraveled buffering genotypes which
may attenuate the unfavorable effect of this variant.
In addition, the individuals with Met allele in the
overweight subclass of CG presented a higher waist
circumference, indicating that Met is mainly linked to
abdominal obesity.
BDNF and blood pressure
Emerging evidences show that BDNF might be involved
in the regulation of arterial pressure via different
pathways. For instance, it has been recently demon-
strated that long-term elevation of BDNF in the para-
ventricular nucleus of the hypothalamus has a major
impact on central regulation of sympathetic activity,
blood pressure and heart rate which is mediated by
ANG II/angiotensin type 1 receptor and angiotensin/
Mas [35]. Dietary high salt intake promotes vasopressin
release which contributes to the elevation of arterial
pressure through BDNF-TrkB-GABAergic signaling sys-
tem [35–37]. BDNF Val66Met modulates hypothalamic-
pituitary-adrenal axis reactivity and regulation, with
women bearing Val/Met genotype and men bearing
Val/Val being particularly vulnerable to psychological
stress [38], an essential etiology for primary hyperten-
sion. These data implicate that higher central or circu-
lating BDNF may account for arterial hypertension
Fig. 2 Overall association of BDNF Val66Met genotypes with metabolic risk parameters. (a) with WC; (b) with BMI; (c) with blood pressure; (d)
with FPG; (e) with TG; (f) with cholesterol levels. TG value was presented as Whiskers 5-95 percentile while the values of other parameters were
presented as Mean ± SD. * indicates P < 0.05. Abbreviations: LG, long-lived group; OG, offspring group; CG, control group; WC, waist circumference;
BMI, body mass index; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; TC, total
cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol
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and Met variant may link to a reduced BDNF level and is fa-
vorable to better blood pressure regulation. However, we de-
tected an elevated but not lowered SBP level in A genotype
carriers in the normal BMI subgroups of the controls and an
elevated DBP level in the hyperglycemic subgroup of OG
when compared to non-A genotype carriers. We have no fur-
ther explanation for this result due to the lack of serum BDNF
level and other functional experiments on this polymorphism.
Fig. 3 Association of BDNF Val66Met genotypes with metabolic risk parameters stratified by sex. With WC (a), BMI (b), FPG (c) and TG (d) in the three
groups investigated; with blood pressure and cholesterol levels in LG (e and f, respectively), in OG (g and h, respectively) and in OC (i and j,
respectively). Not all association panels is presented in this figure. M, males; F, females. Other notes and abbreviations see legends of Fig. 2
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Table 2 Correlation between parameters and the BDNF Val66Met polymorphism
Parameter Relative factor Unstandardized coefficients Standard error Standardized coefficients t P
LG
BMI WC 0.118 0.020 0.296 5.924 0.000
HC 0.184 0.025 0.342 7.333 0.000
DBP −0.498 0.227 −0.072 −2.193 0.029
FBG Sex 0.353 0.106 0.147 3.326 0.001
TG 0.391 0.122 0.143 3.217 0.001
WC 0.012 0.006 0.093 2.094 0.037
SBP Sex 4.815 2.401 0.091 2.005 0.045
DBP TC 1.879 0.586 0.143 3.208 0.001
BMI 0.484 0.162 0.133 2.995 0.003
PP - - - - - -
TC DBP 0.011 0.003 0.139 3.146 0.002
Sex 0.223 0.091 0.110 2.445 0.015
FBG 0.088 0.038 0.103 2.306 0.022
Genotype −0.132 0.063 −0.093 −2.090 0.037
TG FBG 0.058 0.016 0.159 3.556 0.000
DBP 0.004 0.001 0.108 2.425 0.016
HDL-C BMI −0.015 0.007 −0.105 −2.336 0.020
LDL-C DBP 0.009 0.003 0.131 2.930 0.004
Sex 0.230 0.079 0.131 2.921 0.004
OG
BMI WC 0.090 0.037 0.054 2.427 0.016
Sex 0.730 0.144 0.121 5.062 0.000
DBP 0.040 0.006 0.148 6.502 0.000
Age 0.171 0.067 0.059 2.554 0.011
FBG WC −0.041 0.011 −0.173 −3.691 0.000
DBP −0.649 0.131 −0.205 −4.952 0.000
SBP Age 0.902 0.096 0.356 9.377 0.000
BMI 1.522 0.290 0.199 5.251 0.000
Sex −4.215 1.751 −0.091 −2.407 0.016
DBP BMI 1.669 0.172 0.447 9.717 0.000
Sex −4.944 0.838 −0.219 −5.897 0.000
HC −0.924 0.421 −0.085 −2.197 0.028
FBG −0.651 0.235 −0.105 −2.767 0.006
PP Age 0.859 0.083 0.393 10.389 0.000
TC WC −0.037 0.013 −0.213 −2.911 0.004
Age −0.013 0.005 −0.105 −2.670 0.008
BMI 0.069 0.027 0.182 2.588 0.010
DBP −0.008 0.004 −0.084 −2.065 0.039
TG WC 0.057 0.011 0.353 5.282 0.000
Sex −0.076 0.033 −0.151 −2.287 0.023
HDL-C WC −0.012 0.002 −0.189 −4.676 0.000
Sex 0.115 0.045 0.100 2.543 0.011
LDL-C BMI 0.113 0.014 0.328 7.871 0.000
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BDNF Val66Met and glucose metabolism
As mentioned above, previous studies on model animals
had demonstrated that BDNF may suppress food uptake,
improve insulin resistance and maintain glucose homeo-
stasis [28, 29]. Intracerebroventricular or intraperitoneal
administration of BDNF results in a reduction of plasma
glucose level of diabetic or insulin deficient mice [10].
Clinical epidemiological investigation also observed that
the serum BDNF level of diabetic patients were signifi-
cantly lower than that of normal controls and were re-
versely correlated with blood glucose concentration
independent of obesity, indicating the robust relationship
of BDNF and glucose metabolism in that the hypergly-
cemic status of diabetic patients might have repressed the
release of BDNF from the brain [39, 40]. Furthermore,
male BDNF Met/Met carriers with clozapine-induced
metabolic syndrome exhibited significant higher fasting
glucose levels than those with Val/Val or Val/Met geno-
types [14]; carriers of Met allele displayed elevated blood
glucose and predicted lower memory scores [41]. These
observations demonstrated a pronounced influence of
BDNF on glucose homeostasis. However, Bonaccorso et
al. [13] detected no different glucose level between Met
and non-Met carriers in patients with bipolar and schi-
zoaffective disorder, indicating the uncertainty affecting
pattern of BDNF on glucose metabolism. In the present
study, a lowered FPG was only noted in the BDFN GA/
AA carriers of euglycemic and normolipidemic subgroup
of LG but not in any genotype of other groups, implying a
limited effect of BDNF rs6265 on blood glucose modula-
tion in our studying populations. The relatively lower
average FPG levels and lower hyperglycemia prevalence in
these populations might be one of the explanations for
this observation.
BDNF Val66Met and lipid metabolism
Information regarding the influence of BDNF on lipid
modulation is scarce. Tsuchida and colleagues were
some of the researchers who firstly focused on the effect
of BDNF on lipid metabolism and noted that subcutane-
ous injection of BDNF (twice/week) could significantly
improve lipid and glucose profiles in diabetic mice [42].
Table 2 Correlation between parameters and the BDNF Val66Met polymorphism (Continued)
DBP −0.012 0.004 −0.125 −2.996 0.003
CG
BMI WC 0.151 0.025 0.278 5.998 0.000
Age 0.247 0.079 0.084 3.123 0.002
FBG WC 0.186 0.055 0.137 3.359 0.001
SBP Age −4.021 1.801 −0.086 −2.232 0.026
HC 0.706 0.152 0.181 4.631 0.000
DBP Sex 0.541 0.142 0.157 3.822 0.000
FBG −0.650 0.305 −0.087 −2.133 0.033
PP Age −3.783 1.391 −0.104 −2.720 0.007
HC 0.429 0.114 0.141 3.751 0.000
Sex 4.185 1.404 0.113 2.980 0.003
TC BMI 0.045 0.020 0.149 2.310 0.021
Age −0.015 0.004 −0.143 −3.320 0.001
CC −0.040 0.011 −0.275 −3.737 0.000
WC 0.026 0.008 0.243 3.117 0.002
TG BMI 0.076 0.021 0.223 3.586 0.000
Age −0.027 0.005 −0.233 −5.740 0.000
FBG 0.096 0.029 0.131 3.270 0.001
HC −0.058 0.013 −0.315 −4.616 0.000
WC 0.029 0.009 0.246 3.365 0.001
HDL-C Sex −0.003 0.001 −0.108 −2.688 0.007
WC −0.008 0.002 −0.154 −3.827 0.000
LDL-C WC 0.012 0.004 0.120 2.914 0.004
Abbreviations: LG long-lived group, OG offspring group, CG control group, WC waist circumference, HC hip circumference, CC chest circumference, BMI body mass
index, FPG fasting plasma glucose, SBP systolic blood pressure, DBP diastolic blood pressure, PP pulse pressure, TC total cholesterol, TG triglyceride, HDL-C
high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
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In humans, serum BDNF levels were found to be signifi-
cantly higher in type 2 diabetic patients than in the
healthy controls and positively correlated with triglycer-
ide level [43]. As compared to non-Met, BDNF 66Met
carriers with bipolar disorder showed a greater increase
in triglycerides and triglycerides/HDL-C ratio after three
or six months of antipsychotic therapy [13]. We noted
herein similar correlation trend between BDNF Val66-
Met and lipid profiles where Met allele was essentially
linked to elevated triglyceride but lowered HDL-C level
relative to non-Met bearers, particularly in the control
and offspring groups. Tsuchida et al. postulated that
BDNF might enter the brain and act on the hypothal-
amic neurons, leading to activation of sympathetic nerve
system, enhancement of energy expenditure and reduc-
tion of lipid accumulation as does leptin [42]. It is thus
reasonable to assume that the derived Met allele may
account for a lower BDNF level and a reduced energy
consumption and lipid increment in our participants.
BDNF Val66Met and neuroinflammation
Normal aging has been regarded as a chronic and low-
grade pro-inflammatory state, with an over-expression of
systemic inflammatory cytokines including IL-1, IL-6
and TNF-α etc. A number of highly prevalent risk fac-
tors such as obesity, diabetes, hypertension, and athero-
sclerosis are increasingly believed to silently contribute
to systemic- and neuro-inflammation [44–46]. Cerebral
small vessel disease and perfusion deficits resulting from
these pathological conditions may account for the neu-
roinflammation and subsequent neurodegeneration and
cognitive dysfunction [46]. BDNF has been implicated to
play a neuroprotective role in the central nerve system;
low levels of BDNF have been associated with aging and
an array of neurological and psychiatric disorders
[47, 48]. One of the explanations for this protection
in that it counteracts the effects of some inflammatory cy-
tokines such as C-reactive protein [49]. It is thus reason-
able to assume that any BDNF polymorphism with lower
BDNF activity may link to enhanced neuroinflammation
and worsened cognitive outcome. This notion is under-
scored by the observation of Dooley and colleagues who
noted a positive association between C-reactive protein
levels and cognitive depressive symptoms among BDNF
Met carriers of breast cancer survivors [50]. There-
fore, we postulate that the control females who were
enriched with BDNF Met allele in our study may also
have higher inflammatory cytokines and poorer cog-
nition, however this needs to be confirmed in our
future longitudinal follow-up.
Limitations
The first limitation of the present study is that we only fo-
cused on BDNF genotype, without assessing the circulating
BDNF protein levels. There are several intervening aspects
between an individual’s genotype and its function, therefore
an individual’s BDNF genotype does not necessarily deter-
mine BDNF protein levels. Although previous study has
shown a correlation between the Val66Met polymorphism
and circulating BDNF level [51], indicating that BDNF
genotype may serve as a proxy for protein levels at least in
some samples, others have not found this association [52].
The second limitation is that we failed to detect inflamma-
tory biomarkers (e.g. CRP, IL-1, 6, TNF-α) which are very
important parameters in evaluating the association of
BDNF genotype with neuroinflammaging. Finally, we failed
to collect data on cognitive status (e.g. MMSE score) and
life style (e.g. dietary habit, alcohol consumption, smoking
and physical activity) which may be potential confounders
on our results. All these parameters and data will be
considered in our future research on these populations.
Conclusions
In conclusion, the key finding of the current work is that
BDNF Met variant represents more frequently and
correlates with elevated BMI and SBP levels and lowered
HDL-C level in the average population inhabiting the
river basin of Hongshuihe, which may be some of the
contributors to their poorer survivorship as compared to
whom achieve prolonged longevity. Further investi-
gations on the interactions among serum BDNF and
insulin levels and metabolic measures are warranted.
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